NCT07295535 Analysis of the Specificity and Persistence of Nasal Immune Responses to Respiratory Viral Antigens in Immunocompromised and Healthy Cohorts
| NCT ID | NCT07295535 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia |
| Condition | Immuno-modulation |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2027-08-27 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2025-09-01 with a primary completion date of 2027-08-27.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to characterize nasal mucosal immunity to respiratory viruses, such as SARS-CoV-2, in immunocompromised individuals and healthy volunteers. The study involves adults of any sex, between 18 and 90 years old, including both immunocompromised patients with medical conditions or treatments that can affect immune cell functions and healthy controls with no underlying medical conditions declared, no clinical history of immunodeficiency or use of immunosuppressive medications. Researchers will compare immunocompromised participants to healthy volunteers to determine how underlying immunodeficiency and related treatments affect immune cell composition and virus-specific responses.
Eligibility Criteria
Inclusion Criteria: * Informed Consent: Participants must have signed an informed consent form. * Age Range: Participants aged between 18 and 90 years. * Healthy Immunocompetent Donors: no underlying medical conditions declared, no clinical history of immunodeficiency or use of immunosuppressive medications. * Immunocompromised Patients: subjects with medical conditions or treatments associated with significant impairment of the immune system. This may include organ or stem cell transplants, ongoing immunosuppressive therapies, documented genetic immunosuppression. Exclusion Criteria: * Pregnant or lactating women. * Individuals unable to provide informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07295535 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Immuno-modulation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07295535 currently recruiting?
Yes, NCT07295535 is actively recruiting participants. Contact the research team at s.mantovani@smatteo.pv.it for enrollment information.
Where is the NCT07295535 trial being conducted?
This trial is being conducted at Pavia, Italy.
Who is sponsoring the NCT07295535 clinical trial?
NCT07295535 is sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. The trial plans to enroll 40 participants.